+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CRISPR Technology Market by Offering, Delivery Method, Application, End-User - Global Forecast to 2030- Product Image
CRISPR Technology Market by Offering, Delivery Method, Application, End-User - Global Forecast to 2030- Product Image
Sale

CRISPR Technology Market by Offering, Delivery Method, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716152
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The CRISPR Technology Market grew from USD 3.54 billion in 2024 to USD 4.02 billion in 2025. It is expected to continue growing at a CAGR of 13.93%, reaching USD 7.75 billion by 2030.

Unveiling the Frontier of Gene Editing Innovation

In recent years, CRISPR technology has emerged as a disruptive force in biotechnology, enabling unprecedented precision in gene editing and accelerating the advancement of therapeutics, agriculture, and diagnostics. The exponential growth of research activity, coupled with a surge in commercial interest, has propelled CRISPR from a laboratory curiosity to a mainstream driver of innovation. Executive leaders and decision-makers now face the dual challenge of understanding complex scientific developments and translating these breakthroughs into viable business strategies.

This executive summary offers a comprehensive overview of the latest CRISPR landscape, synthesizing key trends, regulatory shifts, and market dynamics. It is designed to equip stakeholders with actionable insights that support informed planning, investment decisions, and competitive positioning. By distilling intricate data into succinct analysis, this report lays the groundwork for strategic agility in a field defined by rapid discovery and intense rivalry.

Navigating the Transformative Shifts Redefining the CRISPR Landscape

Technological breakthroughs continue to redefine the potential of CRISPR, with novel enzyme variants and refined guide RNA constructs enhancing specificity and reducing off-target effects. Recent developments in base editing and prime editing have extended the scope of precise nucleotide modifications, paving the way for therapies targeting genetic disorders previously considered untreatable. In parallel, advances in delivery platforms have improved the efficiency of in vivo and ex vivo applications, overcoming longstanding barriers related to safety and scalability.

Regulatory landscapes are also in flux, as oversight bodies adjust frameworks to accommodate the unique risks and ethical considerations of genome editing. Harmonization efforts among major markets have begun to streamline clinical development pathways, while emerging policies on intellectual property licensing are reshaping collaboration models between academia and industry. These transformative shifts are fueling strategic alliances, mergers, and acquisitions aimed at consolidating technological know-how and market reach.

Assessing the Ripple Effects of US Tariffs on CRISPR Workflows

The implementation of new United States tariffs in 2025 has introduced a notable variable into the global CRISPR supply chain. Import duties on key laboratory reagents and delivery vectors have driven up costs for research institutions and commercial manufacturers alike, prompting a reassessment of procurement strategies. Many organizations have begun to explore alternative sourcing from domestic suppliers or to negotiate volume-based contracts that can absorb incremental expenses without compromising experimental timelines.

In response to tariff-induced cost pressures, forward-looking companies are adopting vertically integrated approaches, investing in in-house production of enzymes, kits, and reagents. This shift not only mitigates exposure to fluctuating trade policies but also fosters greater control over quality and intellectual property. Concurrently, service providers offering gRNA design, vector construction, and screening have adapted their pricing models, emphasizing bundled offerings to maintain client retention while preserving profitability.

Decoding Market Dynamics Through Multidimensional Segmentation Insights

Market segmentation based on offering reveals a bifurcated landscape where product sales and service revenues each play pivotal roles. Within the product domain, enzymes remain foundational tools, while guide RNA constructs and kits and reagents constitute rapidly expanding revenue streams. On the service side, cell line engineering operations are complemented by specialized support in guide RNA design and vector construction, with high-throughput screening services representing an emergent growth vector as demand for custom solutions intensifies.

When viewed through the lens of delivery method, the market divides into ex vivo and in vivo applications. Ex vivo strategies encompass cell line modification and primary cell modification, enabling precise interventions in isolated cell populations before reintroduction into patients or experimental systems. In contrast, in vivo approaches leverage direct editing techniques and sophisticated nanoparticle delivery systems, as well as retargeting vectors engineered to enhance tissue specificity and minimize immunogenicity.

Application-centric analysis highlights four primary domains: agricultural applications, biomedical applications, diagnostics, and industrial biotechnology. Livestock breeding and pest resistance initiatives illustrate how genome editing accelerates crop and animal improvements. In the biomedical arena, drug discovery and development pipelines benefit from rapid gene function validation, while gene therapy programs target a spectrum of inherited disorders. Industrial biotechnology segments, including biofuel production and microbial strain engineering, exploit CRISPR’s capacity to optimize metabolic pathways for commercial bioprocesses. Finally, end-user segmentation underscores the diverse stakeholder base, ranging from academic and research institutes that drive foundational science to biotech and pharmaceutical companies scaling products, as well as contract research organizations that bridge discovery and development phases.

Unearthing Regional Variations Shaping CRISPR Adoption Patterns

In the Americas, robust R&D investments and a favorable regulatory environment have positioned the region at the vanguard of CRISPR innovation. The presence of leading academic centers and a strong venture capital ecosystem fuels a steady flow of translational research, with gene therapy trials and agricultural pilot programs advancing concurrently across the United States and Canada.

Meanwhile, Europe, the Middle East and Africa present a mosaic of regulatory approaches that influence CRISPR adoption. Western Europe’s progressive policy reforms have catalyzed clinical trial initiations and agri-biotech ventures, whereas emerging markets in the Middle East and Africa are beginning to establish foundational infrastructure for gene editing research. Collaborative consortia and public-private partnerships are instrumental in harmonizing ethical frameworks and expanding access to cutting-edge technologies.

Asia-Pacific stands out for its aggressive investment strategies and large-scale deployment of CRISPR solutions. China’s centralized funding model and streamlined approval processes have enabled rapid progression from laboratory research to commercial applications, particularly in agricultural enhancement and therapeutic development. Japan, South Korea and Australia complement these efforts with targeted incentives for precision medicine and bioindustrial innovation, leveraging regional strengths in manufacturing and life sciences.

Profiling Leading Players Driving CRISPR Advancement

Leading companies are consolidating their market positions through strategic partnerships, co-development agreements and acquisitions aimed at expanding their CRISPR toolkits and application portfolios. Enzyme innovators are collaborating with biotech firms to integrate proprietary nucleases into gene therapy pipelines, while established diagnostic companies are incorporating CRISPR-based assays to achieve rapid pathogen detection and multiplexed biomarker analysis.

Service providers are differentiating themselves by offering end-to-end solutions that span guide RNA design, vector construction, cell line engineering and high-throughput screening. This vertical integration not only streamlines client workflows but also builds recurring revenue models. At the same time, pharmaceutical and agricultural giants are investing heavily in internal gene editing platforms to secure competitive advantages in targeted therapeutics and crop resilience programs.

Strategic Imperatives to Capitalize on Evolving Gene Editing Trends

To capitalize on the evolving CRISPR landscape, industry leaders should prioritize building agile infrastructure capable of scaling reagent production and custom services in response to dynamic demand. Investing in modular manufacturing facilities and automated workflows for enzyme and kit assembly will mitigate supply chain disruptions and enable rapid product launches. Strengthening in-house capabilities for gRNA design, vector optimization and cell line engineering can further differentiate service offerings and reduce dependency on external vendors.

Engagement with regulatory authorities and active participation in standardization initiatives will streamline clinical and agricultural approval pathways. Companies that contribute to consensus guidelines on safety, quality control and ethical deployment will gain reputational benefits and early market access. At the same time, forging alliances with academic consortia and technology incubators can accelerate early-stage discovery and de-risk high-value targets.

Finally, diversification across geographic markets and application segments is essential to hedge against policy fluctuations and competitive pressures. By expanding footprint in emerging regions and broadening the scope of applications-from gene therapies to industrial bioprocesses-organizations can capture new revenue streams and reinforce long-term resilience.

Methodical Framework Underpinning the Research Approach

This analysis is grounded in a robust research framework combining primary interviews with industry executives, technical experts and regulatory authorities, alongside exhaustive secondary research spanning scientific journals, patent filings and policy documents. Data triangulation ensures that insights presented here reflect both quantitative metrics and qualitative perspectives from leading stakeholders across the value chain.

Market segmentation and competitive benchmarking were conducted using a bottom-up approach, mapping product portfolios, service capabilities and application footprints. Regional assessments leverage trade statistics, funding records and clinical trial registries to capture geographic nuances. Rigorous validation protocols, including peer reviews and methodological audits, guarantee the accuracy and reliability of the findings.

Synthesizing Key Takeaways to Guide Decision-Making

This executive summary has synthesized the most pertinent developments shaping the CRISPR ecosystem, from technological breakthroughs and tariff implications to segmentation analyses and regional patterns. The insights provided herein offer a strategic blueprint for stakeholders seeking to navigate an industry characterized by rapid innovation and regulatory complexity.

Armed with a clear understanding of market dynamics, companies can make informed decisions about investments, partnerships and operational expansions. The actionable recommendations serve as a roadmap to harness the full potential of CRISPR technologies, ensuring sustained growth and competitive differentiation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Offering
    • Product
      • Enzymes
      • Guide RNA
      • Kits & Reagents
    • Services
      • Cell Line Engineering
      • gRNA Design & Vector Construction
      • Screening Services
  • Delivery Method
    • Ex Vivo
      • Cell Line Modification
      • Primary Cell Modification
    • In Vivo
      • Direct Editing
      • Nanoparticle Delivery
      • Retargeting Vectors
  • Application
    • Agricultural Applications
      • Livestock Breeding
      • Pest Resistance
    • Biomedical Applications
      • Drug Discovery & Development
      • Gene Therapy
    • Diagnostics
    • Industrial Biotechnology
      • Biofuel Production
      • Microbial Strain Engineering
  • End-User
    • Academic & Research Institutes
    • Biotech Companies
    • Contract Research Organizations
    • Pharmaceutical Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
      • Georgia
      • Kentucky
      • Michigan
      • Mississippi
      • New Jersey
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. In-depth overview of CRISPR technology market's evolution significance and current trends driving expansion and barriers
3.2. Quantitative analysis of influential market trends assessing standardized versus localized strategies competitive dynamics and regulatory compliance adaptations
3.3. Comprehensive lifecycle and intellectual property review outlining go-to-market strategies and competitive positioning across CRISPR product lines
3.4. Future market outlook growth opportunities strategic growth options and emerging technology trends shaping CRISPR evolution
4. Market Overview
4.1. Introduction
4.1.1. Defining the CRISPR market with global economic significance growth drivers and innovation opportunities
4.1.2. Evaluating CRISPR market regional dynamics trade impacts and cultural economic geographic influences
4.1.3. Summarizing recent CRISPR market developments patents research investments and industry expansions
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growth of CRISPR companies focusing on personalized medicine and rare genetic diseases
5.1.1. Defining the growth of CRISPR companies targeting personalized medicine and rare genetic diseases with key characteristics and market context
5.1.2. How the rise of CRISPR companies in personalized medicine and rare genetic diseases is driving innovation and opening new market opportunities
5.1.3. Future outlook on the expansion of CRISPR technology for personalized medicine and rare genetic disease treatments with strategic considerations
5.2. Collaborative global research efforts accelerating CRISPR technology commercialization
5.2.1. Clearly defining collaborative global research efforts accelerating CRISPR technology commercialization and its market significance
5.2.2. Analyzing how collaborative global research is transforming the CRISPR market landscape and unlocking business opportunities
5.2.3. Discussing the future trajectory, implications, and risks of collaborative global research in CRISPR commercialization
5.3. Integration of AI and machine learning to optimize CRISPR gene-editing outcomes
5.3.1. Understanding the Rise of AI and Machine Learning Integration in CRISPR Gene Editing
5.3.2. Strategic Adaptations and Competitive Shifts Prompted by AI-Driven CRISPR Optimization
5.3.3. Future Outlook and Strategic Imperatives for AI-Enhanced CRISPR Applications
5.4. CRISPR applications in creating sustainable biofuels and industrial bioproducts
5.4.1. Defining the rise of CRISPR in sustainable biofuels and industrial bioproducts
5.4.2. How CRISPR advances market innovation and expands opportunities in sustainable bioindustries
5.4.3. Future outlook and strategic considerations for CRISPR in sustainable biofuel and bioproduct markets
5.5. Innovations in delivery systems improving CRISPR component targeting and efficiency
5.5.1. Understanding the surge in advanced delivery mechanisms enhancing CRISPR precision and efficacy
5.5.2. Strategic business shifts required to leverage cutting-edge CRISPR delivery technologies
5.5.3. Future trajectory and strategic foresight for CRISPR delivery innovations in coming years
5.6. Regulatory challenges and ethical considerations shaping CRISPR clinical trial approvals
5.6.1. Defining the trend of regulatory and ethical challenges in CRISPR clinical trial approvals
5.6.2. How regulatory and ethical frameworks unlock innovation and market opportunities in CRISPR
5.6.3. Future outlook and strategic recommendations for navigating regulatory and ethical dynamics in CRISPR
5.7. Development of CRISPR tools targeting complex genetic disorders with increased efficacy
5.7.1. Defining the sophisticated advancements in CRISPR tools for tackling complex genetic disorders
5.7.2. How advanced CRISPR tools are revolutionizing genetic therapeutics and expanding market frontiers
5.7.3. Future outlook and strategic imperatives for developing CRISPR tools in complex genetic disorders
5.8. Expansion of CRISPR technology in agricultural biotechnology for crop improvement
5.8.1. Understanding the Surge in CRISPR Adoption for Next-Gen Crop Enhancement
5.8.2. Strategic Shifts and Industry Dynamics Driven by CRISPR Expansion in Crop Biotechnology
5.8.3. Future Trajectory and Strategic Imperatives Amid Growing CRISPR Integration in Crop Science
5.9. Emergence of CRISPR-based diagnostics driving rapid and accurate disease detection
5.9.1. Unveiling CRISPR-Based Diagnostics A New Era of Rapid and Precise Disease Detection
5.9.2. Transforming Healthcare Through CRISPR Diagnostics Opening New Avenues for Innovation and Market Expansion
5.9.3. Future Outlook of CRISPR Diagnostics Navigating Opportunities and Challenges for Sustained Growth
5.10. Advancements in prime editing techniques enhancing CRISPR precision for therapeutic applications
5.10.1. Unlocking Precision: The Rise of Prime Editing in Therapeutic CRISPR Applications
5.10.2. Revolutionizing Gene Therapy: Market Opportunities Sparked by Prime Editing Advancements
5.10.3. Shaping the Future of Precision Medicine: Strategic Considerations for Prime Editing in CRISPR Markets
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.1.1. Barriers Moderating Entry Threats in CRISPR Market Dynamics
6.1.2. Navigating Substitute Technologies Amidst CRISPR Innovation
6.1.3. Supplier Influence Driven by Specialized Inputs and Patent Control
6.1.4. Buyer Bargaining Strength Shaped by Expertise and Alternatives
6.1.5. Intense Rivalry Driving Innovation and Market Evolution
6.2. PESTLE Analysis
6.2.1. Navigating Regulatory Support and Political Stability in CRISPR Advancement
6.2.2. Economic Dynamics Fueling Investment and Market Demand in CRISPR Technology
6.2.3. Social Acceptance and Ethical Debates Shaping CRISPR Market Trajectories
6.2.4. Cutting-Edge Innovations Driving Precision and Expansion in CRISPR
6.2.5. Navigating Complex Legal Landscapes and Intellectual Property Challenges in CRISPR
6.2.6. Environmental Stewardship and Biosafety Concerns Shaping CRISPR Applications
7. Cumulative Impact of United States Tariffs 2025
7.1. Notable United States Tariffs from 2023 to 2025: Key Measures and Timelines
7.2. Historical Background and Economic Rationale Behind U.S. Tariff Policies Since 2018
7.3. Direct Contributions of U.S. Tariffs to Global Inflation Trends
7.4. Implications of Reciprocal Tariffs and Emerging Trade Wars Across Key Regions
7.5. Economic and Political Consequences for Major U.S. Trading Partners
7.6. Long-Term Structural Economic Changes Driven by U.S. Tariff Policies
7.7. Policy Approaches to Alleviate Negative Effects of Tariffs on Economies
8. CRISPR Technology Market, by Offering
8.1. Introduction
8.2. Product
8.2.1. Enzymes
8.2.2. Guide RNA
8.2.3. Kits & Reagents
8.3. Services
8.3.1. Cell Line Engineering
8.3.2. gRNA Design & Vector Construction
8.3.3. Screening Services
9. CRISPR Technology Market, by Delivery Method
9.1. Introduction
9.2. Ex Vivo
9.2.1. Cell Line Modification
9.2.2. Primary Cell Modification
9.3. In Vivo
9.3.1. Direct Editing
9.3.2. Nanoparticle Delivery
9.3.3. Retargeting Vectors
10. CRISPR Technology Market, by Application
10.1. Introduction
10.2. Agricultural Applications
10.2.1. Livestock Breeding
10.2.2. Pest Resistance
10.3. Biomedical Applications
10.3.1. Drug Discovery & Development
10.3.2. Gene Therapy
10.4. Diagnostics
10.5. Industrial Biotechnology
10.5.1. Biofuel Production
10.5.2. Microbial Strain Engineering
11. CRISPR Technology Market, by End-User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Biotech Companies
11.4. Contract Research Organizations
11.5. Pharmaceutical Companies
12. Americas CRISPR Technology Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa CRISPR Technology Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific CRISPR Technology Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AgBiome Inc.
15.3.1.1. Comprehensive overview of AgBiome Inc's strategic market entry evolution and current positioning across global markets
15.3.1.2. In-depth analysis of AgBiome’s flagship biocontrol products and their distinctive advantages for agricultural stakeholders
15.3.1.3. Critical assessment of risks to AgBiome’s growth with strategic recommendations for product diversification and market adoption
15.3.2. Agilent Technologies, Inc.
15.3.2.1. Comprehensive overview of Agilent Technologies' strategic market position and core strengths in life sciences and CRISPR technology
15.3.2.2. In-depth analysis of Agilent Technologies' flagship products aligned with CRISPR research and innovation
15.3.2.3. Critical risk analysis and strategic recommendations for Agilent Technologies to sustain growth in evolving CRISPR markets
15.3.3. BASF SE
15.3.3.1. BASF's Strategic Entry and Current Market Position in CRISPR Technology
15.3.3.2. BASF's Flagship CRISPR Products Drive Agricultural Innovation and Sustainability
15.3.3.3. Navigating Risks and Enhancing BASF’s Competitive Edge in CRISPR Technology
15.3.4. Bayer AG
15.3.4.1. Bayer AG’s strategic foundation and market positioning in CRISPR and biotechnology
15.3.4.2. Innovative CRISPR-driven products tailored to evolving agricultural and healthcare needs
15.3.4.3. Mitigating risks and leveraging strategic opportunities for sustained growth in gene editing
15.3.5. Beam Therapeutics Inc.
15.3.5.1. Trailblazing Base Editing: Beam Therapeutics’ Market Entry and Strategic Evolution
15.3.5.2. Precision Gene Correction Redefined: Deep Dive into Beam Therapeutics’ Flagship Offerings
15.3.5.3. Navigating Future Challenges: Strategic Risks and Growth Fortification for Beam Therapeutics
15.3.6. Benson Hill Biosystems, Inc.
15.3.6.1. Benson Hill's Strategic Market Position and Core Strengths in Agricultural Biotechnology
15.3.6.2. Innovative CropOS® Platform and Gene-Edited Seed Varieties Driving Market Leadership
15.3.6.3. Addressing Regulatory, Competitive, and Market Challenges with Strategic Diversification and Innovation
15.3.7. Caribou Biosciences, Inc.
15.3.7.1. Navigating the Gene Editing Frontier: Caribou Biosciences' Market Entry and Strategic Positioning
15.3.7.2. Cutting-Edge CRISPR Platforms: Caribou’s Flagship Innovations Meeting Market Desires
15.3.7.3. Mitigating Challenges and Building Resilience for Caribou’s Future Growth
15.3.8. Cibus Inc.
15.3.8.1. Cibus Inc's Strategic Market Position and Growth Trajectory in Gene-Edited Agriculture
15.3.8.2. Flagship Gene-Edited Crop Innovations Driving Market Leadership and Customer Value
15.3.8.3. Strategic Risk Management and Growth Enhancement for Sustained Market Leadership
15.3.9. CRISPR Therapeutics AG
15.3.9.1. Establishing a stronghold: CRISPR Therapeutics AG’s market role and strategic footprint
15.3.9.2. Innovative therapies redefining treatment: An in-depth look at CRISPR Therapeutics’ flagship offerings
15.3.9.3. Navigating challenges and seizing opportunities to enhance CRISPR Therapeutics’ market leadership
15.3.10. Danaher Corporation
15.3.10.1. Danaher's Strategic Footprint and Market Leadership in CRISPR Technology
15.3.10.2. Flagship CRISPR Solutions Driving Innovation and Meeting Market Demands
15.3.10.3. Addressing Risks and Leveraging Opportunities for Long-Term Market Leadership
15.3.11. Editas Medicine, Inc.
15.3.11.1. Editas Medicine’s Strategic Role and Market Presence in Gene Editing Therapies
15.3.11.2. Flagship CRISPR-Based Therapies Driving Editas Medicine’s Market Leadership
15.3.11.3. Mitigating Risks and Leveraging Strategic Opportunities for Sustainable Growth
15.3.12. GeneCopoeia, Inc.
15.3.12.1. GeneCopoeia's Strategic Position and Market Footprint in the CRISPR Landscape
15.3.12.2. In-Depth Evaluation of GeneCopoeia's Flagship CRISPR Products and Market Differentiators
15.3.12.3. Navigating Risks and Strategic Growth Opportunities for GeneCopoeia in CRISPR Innovation
15.3.13. Genscript Biotech Corporation
15.3.13.1. Genscript Biotech’s Market Initiation and Strategic Positioning Amidst CRISPR Advancements
15.3.13.2. In-Depth Exploration of Genscript’s Flagship CRISPR Products and Market Differentiators
15.3.13.3. Addressing Risks and Fortifying Genscript’s Strategic Edge for Sustainable Growth
15.3.14. Hera BioLabs
15.3.14.1. Tracing Hera BioLabs' Market Entry, Evolution, and Present Competitive Stance
15.3.14.2. Unveiling Hera BioLabs’ Flagship Products and Their Market Differentiators
15.3.14.3. Mitigating Risks and Enhancing Hera BioLabs’ Strategic Resilience for Future Growth
15.3.15. Intellia Therapeutics Inc.
15.3.15.1. Intellia Therapeutics' Market Entry, Growth Trajectory, and Competitive Positioning
15.3.15.2. In-Depth Examination of Intellia's Flagship CRISPR-Based Therapeutics and Their Market Impact
15.3.15.3. Addressing Regulatory, Scientific, and Competitive Risks to Fortify Intellia's Future Growth Prospects
15.3.16. Lonza Group Ltd.
15.3.16.1. Lonza's Strategic Market Foundations and Expanding Global Footprint
15.3.16.2. Innovative Gene Therapy Manufacturing Services Aligning with CRISPR Market Needs
15.3.16.3. Navigating Growth Risks and Leveraging Innovation for Strategic Expansion
15.3.17. Mammoth Biosciences, Inc.
15.3.17.1. Mammoth Biosciences' Market Position and Strategic Foundations in CRISPR Diagnostics
15.3.17.2. Flagship CRISPR-Based Diagnostic Innovations Driving Mammoth Biosciences' Market Impact
15.3.17.3. Mitigating Growth Risks and Leveraging Strategic Opportunities for Mammoth Biosciences
15.3.18. Merck KGaA
15.3.18.1. Merck KGaA's Strategic Market Entry, Evolution, and Current Position in CRISPR Technology
15.3.18.2. In-depth Insight into Merck KGaA's Flagship CRISPR Products and Their Market Differentiators
15.3.18.3. Addressing Merck KGaA's Risks with Strategic Initiatives to Fortify Future Growth in CRISPR Technology
15.3.19. Pairwise Foods Inc.
15.3.19.1. Pairwise Foods Inc.: From Market Entry to Emerging Innovation Leader in CRISPR-Enhanced Agriculture
15.3.19.2. Transforming Produce with CRISPR: Pairwise’s Flagship Gene-Edited Foods That Redefine Freshness and Nutrition
15.3.19.3. Navigating Regulatory Hurdles and Market Skepticism: Strategic Pathways for Pairwise Foods’ Resilience and Growth
15.3.20. Qiagen NV
15.3.20.1. Qiagen's Strategic Role and Market Positioning in Molecular Diagnostics and CRISPR Technology
15.3.20.2. In-Depth Review of Qiagen's Flagship Molecular Diagnostics and CRISPR Offerings
15.3.20.3. Strategic Risk Management and Growth Opportunities for Qiagen in a Rapidly Evolving Market
15.3.21. Revvity, Inc.
15.3.21.1. Evolution and Market Positioning of Revvity, Inc. in the Life Sciences Sector
15.3.21.2. Revvity’s Flagship Genomic Solutions and Their Unique Market Value
15.3.21.3. Addressing Risks and Strengthening Revvity’s Long-term Competitiveness
15.3.22. Syngenta AG
15.3.22.1. Syngenta AG's Strategic Positioning and Market Presence
15.3.22.2. Syngenta's Flagship Products and Services Meeting Market Demands
15.3.22.3. Syngenta's Strategic Response to Market Challenges
15.3.23. Thermo Fisher Scientific, Inc.
15.3.23.1. Thermo Fisher's strategic entry, market dominance, and global footprint in CRISPR technology
15.3.23.2. In-depth exploration of Thermo Fisher's leading CRISPR offerings and unique market advantages
15.3.23.3. Navigating risks and fortifying Thermo Fisher's CRISPR market position with strategic innovation
15.3.24. ToolGen Inc,
15.3.24.1. ToolGen Inc.'s Strategic Footprint and Market Position in CRISPR Technology
15.3.24.2. Innovative CRISPR Platforms Driving ToolGen’s Market Leadership and Customer Value
15.3.24.3. Mitigating Risks and Seizing Strategic Opportunities for Sustained Growth at ToolGen
15.3.25. Yield10 Bioscience, Inc.
15.3.25.1. Yield10 Bioscience's Strategic Position and Market Foundations in Agricultural Biotechnology
15.3.25.2. In-Depth Examination of Yield10 Bioscience’s Flagship Gene Editing Products and Market Alignment
15.3.25.3. Addressing Growth Risks and Strategic Opportunities to Strengthen Yield10 Bioscience’s Market Leadership
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CRISPR TECHNOLOGY MARKET MULTI-CURRENCY
FIGURE 2. CRISPR TECHNOLOGY MARKET MULTI-LANGUAGE
FIGURE 3. CRISPR TECHNOLOGY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CRISPR TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CRISPR TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CRISPR TECHNOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 71. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 73. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 74. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 75. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 76. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 78. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 79. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 85. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 86. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 87. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 138. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 140. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 141. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 142. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 143. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 145. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 147. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 149. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 152. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 153. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 154. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 157. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. FRANCE CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 171. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 173. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 174. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 175. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 176. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 178. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 179. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 182. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 184. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 185. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 186. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 187. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 189. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. SPAIN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 226. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 228. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 229. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 230. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 231. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 233. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. DENMARK CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 248. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 249. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 250. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 251. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 252. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 253. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 255. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 256. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. QATAR CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 259. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 260. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 261. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 262. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 263. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 264. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. FINLAND CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 292. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 293. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 294. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 295. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 296. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 297. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 299. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 300. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 301. EGYPT CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 302. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 303. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 305. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 306. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 307. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 308. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 310. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 311. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. TURKEY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 325. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 326. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 327. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 328. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 329. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 330. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 332. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 333. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 334. NORWAY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 335. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 336. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 337. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 338. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 339. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 340. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 341. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 342. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 343. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 344. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 345. POLAND CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 346. SWITZERLAND CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 347. SWITZERLAND CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 348. SWITZERLAND CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 349

Companies Mentioned

The companies profiled in this CRISPR Technology market report include:
  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.75 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

CRISPR Gene Editing Market by Type, Application, End User, Delivery Method - Global Forecast to 2030 - Product Image

CRISPR Gene Editing Market by Type, Application, End User, Delivery Method - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
CRISPR & Cas Genes Market by Application, End User, Cas Type, Delivery Method, Technology - Global Forecast to 2030 - Product Image

CRISPR & Cas Genes Market by Application, End User, Cas Type, Delivery Method, Technology - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical, Agricultural), End-use, and Region 2024-2030 - Product Image

CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical, Agricultural), End-use, and Region 2024-2030

  • Report
  • 120 Pages
  • Global
From
CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Kits & Reagents, Cell Line Engineering), By Application (Biomedical, Agricultural), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Kits & Reagents, Cell Line Engineering), By Application (Biomedical, Agricultural), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
CRISPR Technology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

CRISPR Technology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 114 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.